Toumba M, Neocleous V, Fanis P, Tanteles G A, Kyriakidou-Himonas M, Picolos M
Pediatric Endocrine Clinic, IASIS Hospital, Paphos, Cyprus.
Department of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
Hippokratia. 2019 Jul-Sep;23(3):135-139.
Resistance to thyroid hormone (RTH) is a rare dominantly inherited disorder mainly due to variants in the gene leading to decreased end-organ responsiveness to thyroid hormones.
Clinical and molecular characteristics of four patients with RTH are described. Four patients with various phenotypes were studied; two prepubertal boys and two adults (one male and one female). Sequencing analysis of the was performed. All individuals had persistently elevated free thyroxine and/or free triiodothyronine associated with non-suppressed thyroid-stimulating hormone (TSH), and all had non-autoimmune goiters of various sizes. In both adults, antithyroid drugs were previously administered without successful suppression of the thyroid hormones. The 27-year-old female had resting tachycardia as the only symptom. The 35-year-old male had a degree of cognitive impairment and was initially diagnosed with atrial fibrillation. The eight-year-old boy was diagnosed with attention deficit disorder and had resting tachycardia. The oldest boy (age nine years) underwent thyroid function tests as a part of the investigation for obesity and learning difficulties. Direct sequencing analysis of the gene showed three previously reported variants: p.His435Leu (c.1304A>T) in the 35-year-old male, p.Pro453Thr (c.1357C>A) in the oldest boy, and p.Arg438Cys (c.1312C>T) variant in the other two patients.
Various phenotypes characterize common variants in the gene, asymptomatic, thyroid hormone deprivation symptoms, or thyroid hormone excess symptoms. RTH should be suspected in both adults and children with elevated thyroid hormones and not suppressed TSH. A prompt molecular diagnosis and genetic counseling could prevent unnecessary tests and inappropriate treatments. HIPPOKRATIA 2019, 23(3): 135-139.
甲状腺激素抵抗(RTH)是一种罕见的显性遗传性疾病,主要是由于该基因的变异导致终末器官对甲状腺激素的反应性降低。
描述了4例RTH患者的临床和分子特征。研究了4例具有不同表型的患者;2例青春期前男孩和2例成年人(1例男性和1例女性)。对该基因进行了测序分析。所有个体的游离甲状腺素和/或游离三碘甲状腺原氨酸持续升高,同时促甲状腺激素(TSH)未被抑制,且均有不同大小的非自身免疫性甲状腺肿。在2例成年人中,先前曾使用抗甲状腺药物,但未能成功抑制甲状腺激素。27岁女性的唯一症状是静息性心动过速。35岁男性有一定程度的认知障碍,最初被诊断为心房颤动。8岁男孩被诊断为注意力缺陷障碍,并有静息性心动过速。年龄最大的男孩(9岁)作为肥胖和学习困难调查的一部分接受了甲状腺功能测试。对该基因的直接测序分析显示了3个先前报道的变异:35岁男性中的p.His435Leu(c.1304A>T)、年龄最大男孩中的p.Pro453Thr(c.1357C>A)以及另外2例患者中的p.Arg438Cys(c.1312C>T)变异。
该基因的常见变异具有多种表型,包括无症状、甲状腺激素缺乏症状或甲状腺激素过多症状。甲状腺激素升高且TSH未被抑制的成人和儿童均应怀疑患有RTH。及时的分子诊断和遗传咨询可以避免不必要的检查和不适当的治疗。《希波克拉底》2019年,23(3): 135 - 139。